Literature DB >> 17352944

Late stage care in Huntington's disease.

Sheila A Simpson1.   

Abstract

Huntington's disease (HD) is a relentlessly progressive neurodegenerative disease, which is presently incurable. Despite the hope for future therapies that exists for the families, they meantime are aware that there is little that their clinicians can do to delay either onset or progression of the disease. There are unique issues to address in a disorder where patients are aware in advance that their ability to communicate, as well as their cognitive capacity, will become impaired. Most affected individuals have experience of the disease in its late stages because of their parent's and other family member's illness. Many have their own ideas and anxieties about how their own care ought to proceed. There are no published guidelines for management of this stage of disease, although all clinicians involved in the care of HD will have their own experiences to share. This paper describes one method for such management, which includes discussion about placement for care advance directives for feeding and treatment.

Entities:  

Mesh:

Year:  2006        PMID: 17352944     DOI: 10.1016/j.brainresbull.2006.10.022

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

1.  Unified Huntington's disease rating scale for advanced patients: validation and follow-up study.

Authors:  Katia Youssov; Guillaume Dolbeau; Patrick Maison; Marie-Françoise Boissé; Laurent Cleret de Langavant; Raymund A C Roos; Anne-Catherine Bachoud-Lévi
Journal:  Mov Disord       Date:  2013-10       Impact factor: 10.338

Review 2.  Neuroprotection for Huntington's disease: ready, set, slow.

Authors:  Steven M Hersch; H Diana Rosas
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

3.  Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP.

Authors:  Jessica Y Winder; Wilco P Achterberg; Johan Marinus; Sarah L Gardiner; Raymund A C Roos
Journal:  Mov Disord Clin Pract       Date:  2018-08-24

4.  Utilisation of Healthcare and Associated Services in Huntington's disease: a data mining study.

Authors:  Monica Busse; Dr Hasan Al-Madfai; Joyce Kenkre; G Bernhard Landwehrmeyer; Annarita Bentivoglio; Anne Rosser
Journal:  PLoS Curr       Date:  2011-01-21

5.  CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression.

Authors:  Eman M Zaghloul; Olof Gissberg; Pedro M D Moreno; Lee Siggens; Mattias Hällbrink; Anna S Jørgensen; Karl Ekwall; Rula Zain; Jesper Wengel; Karin E Lundin; C I Edvard Smith
Journal:  Nucleic Acids Res       Date:  2017-05-19       Impact factor: 16.971

6.  Gaining insight into the views of outpatients with Huntington's disease regarding their future and the way they deal with their poor prognosis: a qualitative study.

Authors:  Marina R Ekkel; Marja F I A Depla; Els M L Verschuur; Ruth B Veenhuizen; Cees M P M Hertogh; Bregje D Onwuteaka-Philipsen
Journal:  BMC Palliat Care       Date:  2021-01-12       Impact factor: 3.234

7.  Unmet needs for healthcare and social support services in patients with Huntington's disease: a cross-sectional population-based study.

Authors:  Marleen R van Walsem; Emilie I Howe; Kristin Iversen; Jan C Frich; Nada Andelic
Journal:  Orphanet J Rare Dis       Date:  2015-09-28       Impact factor: 4.123

8.  Health Care Delivery Practices in Huntington's Disease Specialty Clinics: An International Survey.

Authors:  Jan C Frich; Daniela Rae; Richard Roxburgh; Zofia H Miedzybrodzka; Mary Edmondson; Erika Bjorklund Pope; LaVonne Goodman; Monica S Haddad; Joe Giuliano; Eugene C Nelson; Mark Guttman; Martha Nance
Journal:  J Huntingtons Dis       Date:  2016-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.